Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6

KRAS and NRAS mutations occur in 45% of colorectal cancers, with combined MAPK pathway and CDK4/6 inhibition identified as a potential therapeutic strategy. In the current study, this combinatorial treatment approach was evaluated in a co-clinical trial in patient-derived xenografts (PDX), and safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorokin, Alexey V., Kanikarla Marie, Preeti, Bitner, Lea, Syed, Muddassir, Woods, Melanie, Manyam, Ganiraju, Kwong, Lawrence N., Johnson, Benny, Morris, Van K., Jones, Philip, Menter, David G., Lee, Michael S., Kopetz, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478530/
https://www.ncbi.nlm.nih.gov/pubmed/35913398
http://dx.doi.org/10.1158/0008-5472.CAN-22-0198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478530/
https://www.ncbi.nlm.nih.gov/pubmed/35913398
http://dx.doi.org/10.1158/0008-5472.CAN-22-0198

Ejemplares similares